New combo therapy aims to save rectums in advanced cancer
NCT ID NCT07347951
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a new approach for patients with a specific type of locally advanced rectal cancer (MSS-type). Participants will receive a short course of radiation, followed by chemotherapy combined with two additional drugs: serplulimab (an immunotherapy) and bevacizumab (a targeted therapy). The goal is to see if this combination can shrink or eliminate the tumor before surgery, potentially allowing more patients to avoid a permanent colostomy and preserve their rectum. The study will enroll 30 people and track how many achieve a complete response, as well as side effects and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Short-course radiotherapy, CAPOX chemotherapy, serplulimab (immunotherapy), and bevacizumab (targeted therapy)
What this could lead to
If successful, this combination could increase the chance of eliminating the tumor before surgery, potentially allowing more patients to avoid permanent colostomy and preserve their rectum.
What could go wrong
This is a small, early-phase study with only 30 participants, so results may not apply to everyone. Combining multiple treatments also raises the risk of serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Wenzhou Medical University
RECRUITINGWenzhou, Zhejiang, 325000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••